NYSE:ZBH

Zimmer Biomet (ZBH) Stock Price, News & Analysis

Zimmer Biomet logo
$101.22 -0.25 (-0.25%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$100.98 -0.24 (-0.24%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Zimmer Biomet Stock (NYSE:ZBH)

Advanced

Key Stats

Today's Range
$100.82
▼
$103.87
50-Day Range
$87.98
▼
$109.46
52-Week Range
$79.12
▼
$112.54
Volume
2.96 million shs
Average Volume
2.64 million shs
Market Capitalization
$19.16 billion
P/E Ratio
25.62
Dividend Yield
0.95%
Price Target
$114.32
Consensus Rating
Hold

Company Overview

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications.

The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.

Headquartered in Warsaw, Indiana, Zimmer Biomet traces its history to Zimmer, founded in 1927. The company took its current form in 2015, when Zimmer completed its acquisition of Biomet. It serves healthcare markets around the world, and Ivan Tornos became president and chief executive officer in 2023.

AI Generated. May Contain Errors.

Zimmer Biomet Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

ZBH MarketRank™: 
3.7480734202 of 5 stars

Zimmer Biomet scored higher than 75% of companies evaluated by MarketBeat, and ranked 80th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zimmer Biomet has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 8 buy ratings, 15 hold ratings, and 1 sell rating.

  • Upside Potential

    Zimmer Biomet has a consensus price target of $114.32, representing about 12.9% upside from its current price of $101.22.

  • Amount of Analyst Coverage

    Zimmer Biomet has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Zimmer Biomet's stock forecast and price target.
  • Earnings Growth

    Earnings for Zimmer Biomet are expected to grow by 3.97% in the coming year, from $8.56 to $8.90 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zimmer Biomet is 25.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.19.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zimmer Biomet is 25.62, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.56.

  • Price to Earnings Growth Ratio

    Zimmer Biomet has a PEG Ratio of 2.37. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Zimmer Biomet has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Zimmer Biomet's valuation and earnings.
  • Percentage of Shares Shorted

    4.17% of the float of Zimmer Biomet has been sold short.
  • Short Interest Ratio / Days to Cover

    Zimmer Biomet has a short interest ratio ("days to cover") of 3.89, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Zimmer Biomet has recently decreased by 1.40%, indicating that investor sentiment is improving.
  • Dividend Yield

    Zimmer Biomet has a dividend yield of 0.95%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Zimmer Biomet does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Zimmer Biomet is 24.30%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Zimmer Biomet will have a dividend payout ratio of 10.79% next year. This indicates that Zimmer Biomet will be able to sustain or increase its dividend.

  • Read more about Zimmer Biomet's dividend.
  • News Sentiment

    Zimmer Biomet has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Zimmer Biomet this week, compared to 5 articles on an average week.
  • Search Interest

    5 people have searched for ZBH on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 2 people have added Zimmer Biomet to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zimmer Biomet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $824,028.00 in company stock.

  • Percentage Held by Insiders

    1.28% of the stock of Zimmer Biomet is held by insiders.

  • Percentage Held by Institutions

    88.89% of the stock of Zimmer Biomet is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Zimmer Biomet's insider trading history.
Receive ZBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zimmer Biomet and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZBH Stock News Headlines

Zimmer Biomet: Fixing Its Own House While Its Rivals Are Distracted
Zimmer Biomet: Solid Sales And Cash Flow Drive A Buy
CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
Can Zimmer Biomet Holdings (ZBH) Stay Cheap If Cash Flow Delivers?
Zimmer Biomet (NYSE:ZBH) Stock Rating Upgraded by Wells Fargo & Company
See More Headlines

ZBH Stock Analysis - Frequently Asked Questions

Zimmer Biomet's stock was trading at $89.94 at the start of the year. Since then, ZBH shares have increased by 12.5% and is now trading at $101.2180.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) released its quarterly earnings data on Wednesday, November, 4th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.02. The business's revenue was up 3.1% on a year-over-year basis.
Read the conference call transcript
.

Zimmer Biomet subsidiaries include Respondwell, Clinical Graphics, CD Diagnostics, Medtech SAS, Compression Therapy Products, LDR Holding, Cayenne Medical, and more.

Top institutional shareholders of Zimmer Biomet include Dodge & Cox (12.01%), State Street Corp (4.69%), American Century Companies Inc. (1.25%) and Equity Investment Corp (0.93%). Insiders that own company stock include Chad F Phipps, Sang Yi and Lori Winkler.
View institutional ownership trends
.

Shares of ZBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zimmer Biomet investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Pfizer (PFE), Salesforce (CRM), Walt Disney (DIS), Intel (INTC) and JPMorgan Chase & Co. (JPM).

Company Calendar

Record date for 10/30 Dividend
9/30/2026
Ex-Dividend for 10/30 Dividend
9/30/2026
Dividend Payable
10/30/2026
Last Earnings
11/04/2026
Today
11/22/2026
Fiscal Year End
12/31/2026
Next Earnings (Estimated)
2/09/2027

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSE:ZBH
Previous Symbol
NYSE:ZMH
CIK
1136869
Employees
17,000
Year Founded
1927

Price Target and Rating

High Price Target
$140.00
Low Price Target
$93.00
Potential Upside/Downside
+12.9%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
24 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.95
Trailing P/E Ratio
25.62
Forward P/E Ratio
11.37
P/E Growth
2.37
Net Income
$705.20 million
Net Margins
8.95%
Pretax Margin
10.32%
Return on Equity
13.02%
Return on Assets
7.17%

Debt

Debt-to-Equity Ratio
0.49
Current Ratio
1.46
Quick Ratio
0.79

Sales & Book Value

Annual Sales
$8.23 billion
Price / Sales
2.33
Cash Flow
$13.75 per share
Price / Cash Flow
7.36
Book Value
$67.24 per share
Price / Book
1.51

Miscellaneous

Outstanding Shares
189,250,000
Free Float
186,832,000
Market Cap
$19.16 billion
Optionable
Optionable
Beta
0.50

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NYSE:ZBH) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners